Podocytopathies

JB Kopp, HJ Anders, K Susztak, MA Podestà… - Nature Reviews …, 2020 - nature.com
Podocytopathies are kidney diseases in which direct or indirect podocyte injury drives
proteinuria or nephrotic syndrome. In children and young adults, genetic variants in> 50 …

Novel paradigms in systemic lupus erythematosus

T Dörner, R Furie - The Lancet, 2019 - thelancet.com
The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

A Trautmann, O Boyer, E Hodson, A Bagga… - Pediatric …, 2023 - Springer
Idiopathic nephrotic syndrome is the most frequent pediatric glomerular disease, affecting
from 1.15 to 16.9 per 100,000 children per year globally. It is characterized by massive …

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse …

DC Wheeler, N Jongs, BV Stefansson… - Nephrology Dialysis …, 2022 - academic.oup.com
Background Despite renin–angiotensin–aldosterone system blockade and
immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses …

Corticosteroid therapy for nephrotic syndrome in children

D Hahn, SM Samuel, NS Willis… - … of systematic reviews, 2024 - cochranelibrary.com
Background In nephrotic syndrome, protein leaks from the blood into the urine through the
glomeruli, resulting in hypoproteinaemia and generalised oedema. While most children with …

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial

N Jourde-Chiche, N Costedoat-Chalumeau… - Annals of the …, 2022 - ard.bmj.com
Objectives Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus
(SLE). Severe (proliferative) forms of LN are treated with induction immunosuppressive …

KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS

BH Rovin, IM Ayoub, TM Chan, ZH Liu… - Kidney …, 2024 - kidney-international.org
This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies

C Nester, GB Appel, AS Bomback… - American journal of …, 2022 - karger.com
Abstract Introduction: C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive
nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with …

Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a randomized clinical trial

Z Zheng, H Zhang, X Peng, C Zhang, C Xing… - JAMA Network …, 2022 - jamanetwork.com
Importance Lupus nephritis (LN) is typically treated with intravenous cyclophosphamide
(IVCY), which is associated with serious adverse effects. Tacrolimus may be an alternative …